Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra.
Exposure of human fetuses to man-made estrogenic chemicals can occur through several sources. For example, fetal exposure to ethinylestradiol occurs because each year approximately 3% of women taking oral contraceptives become pregnant. Exposure to the estrogenic chemical bisphenol A occurs through food and beverages because of significant leaching from polycarbonate plastic products and the lining of cans. We fed pregnant CD-1 mice ethinylestradiol (0.1 microg/kg per day) and bisphenol A (10 microg/kg per day), which are doses below the range of exposure by pregnant women. In male mouse fetuses, both ethinylestradiol and bisphenol A produced an increase in the number and size of dorsolateral prostate ducts and an overall increase in prostate duct volume. Histochemical staining of sections with antibodies to proliferating cell nuclear antigen and mouse keratin 5 indicated that these increases were due to a marked increase in proliferation of basal epithelial cells located in the primary ducts. The urethra was malformed in the colliculus region and was significantly constricted where it enters the bladder, which could contribute to urine flow disorders. These effects were identical to those caused by a similar dose (0.1 microg/kg per day) of the estrogenic drug diethylstilbestrol (DES), a known human developmental teratogen and carcinogen. In contrast, a 2,000-fold higher DES dose completely inhibited dorsolateral prostate duct formation, revealing opposite effects of high and low doses of estrogen. Acceleration in the rate of proliferation of prostate epithelium during fetal life by small amounts of estrogenic chemicals could permanently disrupt cellular control systems and predispose the prostate to disease in adulthood.
Timms
Barry G
BG
Division of Basic Biomedical Sciences, University of South Dakota School of Medicine, Vermillion, SD 57069, USA.
Howdeshell
Kembra L
KL
Barton
Lesley
L
Bradley
Sarahann
S
Richter
Catherine A
CA
vom Saal
Frederick S
FS
D000818:Animals; D001559:Benzhydryl Compounds; D049109:Cell Proliferation; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004054:Diethylstilbestrol / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D053569:Keratin-15; D053555:Keratin-5; D007633:Keratins / Q000378:metabolism; D008297:Male; D018811:Maternal Exposure; D051379:Mice; D008954:Models, Biological; D010636:Phenols / Q000009:adverse effects*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects; D011297:Prenatal Exposure Delayed Effects; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011467:Prostate / Q000187:drug effects* / Q000196:embryology* / Q000473:pathology; D014521:Urethra / Q000187:drug effects* / Q000196:embryology*; D000098826:Bisphenol A Compounds
D001559:Benzhydryl Compounds; D003276:Contraceptives, Oral; D004054:Diethylstilbestrol; D004997:Ethinyl Estradiol; D053569:Keratin-15; D053555:Keratin-5; D007633:Keratins; D010636:Phenols; D018809:Proliferating Cell Nuclear Antigen; C503940:KRT5 protein, human; C492053:Krt15 protein, mouse; C006780:bisphenol A; D000098826:Bisphenol A Compounds